Status: Recruiting
68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)
The purpose of this study is to look at the effects (good and bad) of a drug called 177Lu-PSMA-617 (also known as the study drug) when given to participants who have prostate specific membrane antigen (PSMA) positive liver cancer.
Participants needed: 10
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Melissa LumishUpdated: May 8, 2026Locations: 1
Eligibility criteria
Participants must have histologically, cytologically or radiographically confirm... [+7]
Participants receiving any other investigational agents. [+11]